18.02.2010 • NewsAkzoNobelBilanz

Akzo Nobel Sees Increase in Q4 Operating Profit

Akzo Nobel has reported a 10% drop in revenue in 2009 to €13,893 million. However, the company is looking at a smaller net loss for Q4 2009 (€60 million) over the same period a year ago (€1.51 billion). The company has also reported a 7% decrease in Q4 sales. Q4 operating profit was up by 4%.

Akzo said that demand has recovered to year-ago levels, but "we believe the recovery is fragile and will be slow," CEO Hans Wijers said. "We continue to focus on customers, cost reduction and cash generation, but investments to capture growth will remain a priority - particularly in high growth markets."

AkzoNobel is looking at €540 million in cost cuts and synergies from its acquisition of ICI by the end of next year. Wijers also said the company is on track to meet its goal to achieve a target Ebitda margen of 14% by the end of 2011.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.